From the Guidelines
Izervay is administered as a 0.5 mL injection containing 50 mg of tetravalent influenza vaccine, given intramuscularly, typically in the deltoid muscle of the upper arm, for patients 65 years of age and older, as stated in the most recent guidelines 1. The medication is delivered directly into the muscle by a healthcare professional in a clinical setting. This dosage has been established as the effective therapeutic amount for preventing influenza in older adults. Before administration, the skin is typically prepared with an antiseptic solution to reduce the risk of infection. Patients should be monitored for potential side effects such as pain, redness, or swelling at the injection site following the injection. The single dose schedule is important for maintaining therapeutic levels of the medication in the body to effectively prevent influenza. Key considerations for administration include:
- Patient age: 65 years and older
- Dose: 0.5 mL containing 50 mg of tetravalent influenza vaccine
- Route of administration: intramuscularly in the deltoid muscle
- Frequency: single dose It is essential to follow the recommended dosage and administration guidelines to ensure the effectiveness of the vaccine and minimize potential side effects, as supported by the most recent and highest quality study 1.
From the Research
Dosage Information
- There is no specific information available on the dosage of Izervay (avacincaptad pegol) in the provided studies 2, 3, 4, 5, 6.
- The studies primarily focus on the approval, mechanism of action, and potential benefits of Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, without mentioning the recommended dosage.
- Further research or consultation of external sources may be necessary to determine the appropriate dosage of Izervay for patients.